| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.098 | 0.04 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.086 | 0.06 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.082 | 0.08 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.077 | 0.09 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.079 | 0.09 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.076 | 0.1 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.047 | 0.3 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.041 | 0.4 |